Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Retained Earnings (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Retained Earnings for 6 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 101.82% to $4.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.3 million, a 101.82% increase, with the full-year FY2025 number at $4.3 million, up 101.82% from a year prior.
  • Retained Earnings was $4.3 million for Q4 2025 at Janux Therapeutics, up from -$319.4 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $4.3 million in Q4 2025 to a low of -$319.4 million in Q3 2025.
  • A 5-year average of -$119.5 million and a median of -$127.9 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: plummeted 40814.81% in 2022, then surged 101.82% in 2025.
  • Janux Therapeutics' Retained Earnings stood at -$270000.0 in 2021, then tumbled by 40814.81% to -$110.5 million in 2022, then plummeted by 52.77% to -$168.8 million in 2023, then plummeted by 40.88% to -$237.8 million in 2024, then surged by 101.82% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Retained Earnings are $4.3 million (Q4 2025), -$319.4 million (Q3 2025), and -$295.1 million (Q2 2025).